Donepezil in the treatment of progressive supranuclear palsy.

Saved in:
Bibliographic Details
Title: Donepezil in the treatment of progressive supranuclear palsy.
Authors: Fabbrini, G., Barbanti, P., Bonifati, V., Colosimo, C., Gasparini, M., Vanacore, N., Meco, G.
Source: Acta Neurologica Scandinavica. Feb2001, Vol. 103 Issue 2, p123-125. 3p.
Subjects: Cholinesterase inhibitors, Progressive supranuclear palsy, Drug therapy
Abstract: Objectives – To evaluate the effect of 3 month therapy with donepezil, a centrally acting cholinesterase inhibitor, on cognitive performances, motor function and daily living activities in progressive supranuclear palsy (PSP). Materials and methods – Six patients with a diagnosis of PSP were evaluated at baseline and after 3 months of treatment with donepezil, 10 mg given at bedtime. Cognitive functions, motor symptoms and daily activities were evaluated by means of appropriate rating scales. Results – Donepezil was not effective on cognitive dysfunction and did not change ratings of daily living. Parkinsonian symptoms were unaffected by donepezil treatment. Conclusions – Cholinergic replacement therapy alone is not likely to improve symptoms in a disorder characterized by a more widespread impairment of monoaminergic systems. Larger studies may be necessary to confirm the lack of effect of donepezil in this disorder. [ABSTRACT FROM AUTHOR]
Copyright of Acta Neurologica Scandinavica is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
FullText Links:
  – Type: pdflink
Text:
  Availability: 0
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 5788298
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Donepezil in the treatment of progressive supranuclear palsy.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Fabbrini%2C+G%2E%22">Fabbrini, G.</searchLink><br /><searchLink fieldCode="AR" term="%22Barbanti%2C+P%2E%22">Barbanti, P.</searchLink><br /><searchLink fieldCode="AR" term="%22Bonifati%2C+V%2E%22">Bonifati, V.</searchLink><br /><searchLink fieldCode="AR" term="%22Colosimo%2C+C%2E%22">Colosimo, C.</searchLink><br /><searchLink fieldCode="AR" term="%22Gasparini%2C+M%2E%22">Gasparini, M.</searchLink><br /><searchLink fieldCode="AR" term="%22Vanacore%2C+N%2E%22">Vanacore, N.</searchLink><br /><searchLink fieldCode="AR" term="%22Meco%2C+G%2E%22">Meco, G.</searchLink>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Acta+Neurologica+Scandinavica%22">Acta Neurologica Scandinavica</searchLink>. Feb2001, Vol. 103 Issue 2, p123-125. 3p.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22Cholinesterase+inhibitors%22">Cholinesterase inhibitors</searchLink><br /><searchLink fieldCode="DE" term="%22Progressive+supranuclear+palsy%22">Progressive supranuclear palsy</searchLink><br /><searchLink fieldCode="DE" term="%22Drug+therapy%22">Drug therapy</searchLink>
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: Objectives – To evaluate the effect of 3 month therapy with donepezil, a centrally acting cholinesterase inhibitor, on cognitive performances, motor function and daily living activities in progressive supranuclear palsy (PSP). Materials and methods – Six patients with a diagnosis of PSP were evaluated at baseline and after 3 months of treatment with donepezil, 10 mg given at bedtime. Cognitive functions, motor symptoms and daily activities were evaluated by means of appropriate rating scales. Results – Donepezil was not effective on cognitive dysfunction and did not change ratings of daily living. Parkinsonian symptoms were unaffected by donepezil treatment. Conclusions – Cholinergic replacement therapy alone is not likely to improve symptoms in a disorder characterized by a more widespread impairment of monoaminergic systems. Larger studies may be necessary to confirm the lack of effect of donepezil in this disorder. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of Acta Neurologica Scandinavica is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=5788298
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1034/j.1600-0404.2001.103002123.x
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 3
        StartPage: 123
    Subjects:
      – SubjectFull: Cholinesterase inhibitors
        Type: general
      – SubjectFull: Progressive supranuclear palsy
        Type: general
      – SubjectFull: Drug therapy
        Type: general
    Titles:
      – TitleFull: Donepezil in the treatment of progressive supranuclear palsy.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Fabbrini, G.
      – PersonEntity:
          Name:
            NameFull: Barbanti, P.
      – PersonEntity:
          Name:
            NameFull: Bonifati, V.
      – PersonEntity:
          Name:
            NameFull: Colosimo, C.
      – PersonEntity:
          Name:
            NameFull: Gasparini, M.
      – PersonEntity:
          Name:
            NameFull: Vanacore, N.
      – PersonEntity:
          Name:
            NameFull: Meco, G.
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 02
              Text: Feb2001
              Type: published
              Y: 2001
          Identifiers:
            – Type: issn-print
              Value: 00016314
          Numbering:
            – Type: volume
              Value: 103
            – Type: issue
              Value: 2
          Titles:
            – TitleFull: Acta Neurologica Scandinavica
              Type: main
ResultId 1